Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP596767.RApVsmNnjT1nnOREfqrvCFv9kUUK60lv25dZLZK6_yHy0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP596767.RApVsmNnjT1nnOREfqrvCFv9kUUK60lv25dZLZK6_yHy0130_assertion type Assertion NP596767.RApVsmNnjT1nnOREfqrvCFv9kUUK60lv25dZLZK6_yHy0130_head.
- NP596767.RApVsmNnjT1nnOREfqrvCFv9kUUK60lv25dZLZK6_yHy0130_assertion wasGeneratedBy ECO_0000203 NP596767.RApVsmNnjT1nnOREfqrvCFv9kUUK60lv25dZLZK6_yHy0130_provenance.
- NP596767.RApVsmNnjT1nnOREfqrvCFv9kUUK60lv25dZLZK6_yHy0130_assertion wasDerivedFrom befree-20150227 NP596767.RApVsmNnjT1nnOREfqrvCFv9kUUK60lv25dZLZK6_yHy0130_provenance.
- NP596767.RApVsmNnjT1nnOREfqrvCFv9kUUK60lv25dZLZK6_yHy0130_assertion SIO_000772 15041728 NP596767.RApVsmNnjT1nnOREfqrvCFv9kUUK60lv25dZLZK6_yHy0130_provenance.
- NP596767.RApVsmNnjT1nnOREfqrvCFv9kUUK60lv25dZLZK6_yHy0130_assertion evidence source_evidence_literature NP596767.RApVsmNnjT1nnOREfqrvCFv9kUUK60lv25dZLZK6_yHy0130_provenance.
- NP596767.RApVsmNnjT1nnOREfqrvCFv9kUUK60lv25dZLZK6_yHy0130_assertion description "[Overexpression of CYR61, CTGF, WISP-1, and NOV occurred in 48% (32 of 66), 58% (38 of 66), 36% (24 of 66), and 15% (10 of 66) of primary gliomas, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP596767.RApVsmNnjT1nnOREfqrvCFv9kUUK60lv25dZLZK6_yHy0130_provenance.